1,721,285 research outputs found
Differentiated thyroid cancer incidentally detected by 18F-FDG PET/CT: Patient's future in a hot-spot?
Full text linkCognitive reserve and clinical expression of Alzheimer's disease: evidence and implications for brain PET imaging
No full textCognitive reserve (CR) refers to the hypothesized capacity of an adult brain to cope with brain damage in order to minimize symptomatology. The present review is focused on the contribution of brain PET in the understanding of the influence of CR on the disassociation between cognition and degree of Alzheimer's disease (AD) pathology. Theories for the explanation CR-related mechanism as well as PET imaging evidence for the existence of CR are described. Moreover functional imaging studies investigating specific networks for CR both in healthy subjects and AD patients are discussed. Finally implications for amyloid PET imaging are presented
Is dopamine transporter invariably impaired at the time of diagnosis in dementia with Lewy bodies?
Full text linkErratum to: Dual-phase amyloid PET: hitting two birds with one stone
No full textThe original version on this paper contained an error. The names of all authors were displayed incorrectly. The names and surnames of the authors are inversed. Correct presentation is given below. Valentina Garibotto Silvia Morbelli Marco Pagani
Imaging biomarkers in Alzheimer's disease: Added value in the clinical setting
No full textOver the last 20 years the availability of magnetic resonance imaging and positron-emission tomography technologies as well as of cerebrospinal fluid biomarkers has allowed research and clinical approach to Alzheimer's disease (AD) to move towards the earliest manifestations of the disease. This new approach resulted in an increasing knowledge about in-vivo biological and neuropathological processes of each phase of the AD-related damage from preclinical, to mild cognitive impairment, and finally to dementia due to AD. The present narrative review deals with the available data as well as with the unsolved issued related to the incorporation of AD biomarkers into the clinical practice. Ongoing research efforts aiming to better define and implement the use of imaging AD biomarkers in clinical practice according to a patient-centered approach and sustainability for clinical-care systems are also discussed
Amyloid PET Imaging: Standardization and Integration with Other Alzheimer’s Disease Biomarkers
No full textAmyloid plaques are a neuropathologic hallmark of Alzheimerâs disease (AD), which can be imaged through positron emission tomography (PET) technology using radiopharmaceuticals that selectively bind to the fibrillar aggregates of amyloid-Î2 plaques (Amy-PET). Several radiotracers for amyloid PET have been investigated, including11C-Pittsburgh compound B and the18F-labeled compounds such as18F-florbetaben,18F-florbetapir, and18F-flutemetamol. Besides the injected radiotracer, images can be interpreted by means of visual/qualitative, semiquantitative, and quantitative criteria. Here we summarize the main differences between the available radiotracers for Amy-PET, the proposed interpretation criteria, and analytical methods
FDG PET Unveils the Course of Paraneoplastic Cerebellar Degeneration: A Semiquantitative Analysis
No full textIn paraneoplastic cerebellar degeneration (PCD), the standard diagnostic workup might be inconclusive, especially in seronegative subtypes. Brain 18F-FDG PET is an accurate supportive diagnostic tool in immune-mediated disorders, but findings in PCD are controversial. Semiquantitative analysis of 18F-FDG PET can meaningfully assist visual assessment in different neurological conditions and has been mainly applied to disclose regional hypometabolism. We describe a seronegative PCD associated with small cell lung cancer in which 18F-FDG PET semiquantitative analysis accurately disclosed the longitudinal pathological changes of brain metabolism occurring in the acute and posttreatment remission stages and paralleling clinical impairment and response to treatment
Serum neurofilament light chain rate of change in Alzheimer's disease: potentials applications and notes of caution
No full text- …
